Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPMAGNANI, Diogo M.ROGERS, Thomas F.BEUTLER, NathanRICCIARDI, Michael J.BAILEY, Varian K.GONZALEZ-NIETO, LucasBRINEY, BryanSOK, DevinLE, KhoaSTRUBEL, AlexanderGUTMAN, Martin J.PEDRENO-LOPEZ, NuriaGRUBAUGH, Nathan D.SILVEIRA, Cassia G. T.MAXWELL, Helen S.DOMINGUES, AlineMARTINS, Mauricio A.LEE, David E.OKWUAZI, Erica E.JEAN, SherrieSTROBERT, Elizabeth A.CHAHROUDI, AnnSILVESTRI, GuidoVANDERFORD, Thomas H.KALLAS, Esper G.DESROSIERS, Ronald C.BONALDO, Myrna C.WHITEHEAD, Stephen S.BURTON, Dennis R.WATKINS, David I.2017-12-122017-12-122017SCIENCE TRANSLATIONAL MEDICINE, v.9, n.410, article ID eaan8184, 7p, 20171946-6234https://observatorio.fm.usp.br/handle/OPI/24186Therapies to prevent maternal Zika virus (ZIKV) infection and its subsequent fetal developmental complications are urgently required. We isolated three potent ZIKV-neutralizing monoclonal antibodies (nmAbs) from the plasma-blasts of a ZIKV-infected patient-SMZAb1, SMZAb2, and SMZAb5-directed against two different domains of the virus. We engineered these nmAbs with Fc LALA mutations that abrogate Fc gamma receptor binding, thus eliminating potential therapy-mediated antibody-dependent enhancement. We administered a cocktail of these three nmAbs to nonhuman primates 1 day before challenge with ZIKV and demonstrated that the nmAbs completely prevented viremia in serum after challenge. Given that numerous antibodies have exceptional safety profiles in humans, the cocktail described here could be rapidly developed to protect uninfected pregnant women and their fetuses.engrestrictedAccessdengue virusdependent enhancementstructural basisrhesus-monkeysprotectionvaccinediseasebindingmicearticleCopyright AMER ASSOC ADVANCEMENT SCIENCE10.1126/scitranslmed.aan8184Cell BiologyMedicine, Research & Experimental1946-6242